IVIhor Vynnychenko

Ihor Vynnychenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ihor Vynnychenko has a total of 205 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    STK11 AND KEAP1 MUTATIONS AS PROGNOSTIC AND PREDICTIVE MARKERS OF IMMUNOTHERAPY EFFICACY IN NON-SMALL CELL LUNG CANCER

    by I. Vynnychenko, V. Kovchun, O. Diedova, O. Muzhychuk

    Non-small cell lung cancer remains one of the leading causes of cancer-related mortality worldwide. The introduction of immune checkpoint inhibitors has significantly improved treatment outcomes; however, the efficacy of immunotherapy remains heterogeneous, necessitating the search for new predictive biomarkers.Purpose – to analyze current data on the role of STK11 and KEAP1 mutations as prognostic and predictive markers of immunotherapy efficacy in non-small cell lung cancer and their impact on the tumor immune microenvironment and treatment outcomes.Materials and Methods. A literature review was conducted using the PubMed database covering the period from 2020 to 2025. Clinical studies, meta-analyses, and experimental works investigating the impact of STK11 and KEAP1 mutations on the efficacy of immune checkpoint inhibitors were selected.Results. STK11 and KEAP1 mutations are detected in approximately 15-20% and 10-15% of NSCLC cases, respectively, and are associated with an unfavorable prognosis. Loss of STK11 function leads to metabolic reprogramming and the development of an immunologically “cold” microenvironment with low CD8+ T-lymphocyte infiltration. KEAP1 inactivation activates NRF2-dependent antioxidant mechanisms and suppresses interferon signaling. STK11/KEAP1 co-mutations define the most aggressive tumor subtype. The poorest outcomes are observed with PD-1/PD-L1 inhibitor monotherapy, where response rates are significantly lower and survival is reduced. Chemoimmunotherapy partially improves outcomes, whereas dual immunotherapy demonstrates moderate efficacy improvement. Combination strategies targeting metabolic resistance mechanisms and activation of innate immunity appear to be the most promising approaches.Conclusions. STK11 and KEAP1 mutations are important negative prognostic and predictive markers in NSCLC that contribute to the formation of an immunosuppressive microenvironment and reduced immunotherapy efficacy. Determination of their status may improve treatment personalization and optimize therapeutic strategy selection.

  • Top Cited Papers

    Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

    by Enriqueta Felip, Nasser Altorki, Caicun Zhou, Eric Vallières, Tibor Csoszi, Ihor O. Vynnychenko, Oleksandr Goloborodko, Achim Rittmeyer, Martin Reck, Alex Martinez-Marti, et al.

    IMpower010 (ClinicalTrials.gov identifier: NCT02486718 ) previously showed that atezolizumab improved disease-free survival (DFS) versus best supportive care (BSC) after adjuvant chemotherapy in patients with resected non–small cell lung cancer (NSCLC). We report DFS final analysis, second overall survival (OS) interim analysis, and safety with a ≥5-year follow-up. Patients with completely resected stage IB-IIIA NSCLC were randomly assigned to atezolizumab (1,200 mg once every 3 weeks, 16 cycles) or BSC after platinum-based chemotherapy. At clinical cutoff (January 26, 2024), stratified hazard ratios (HRs; 95% CI) for DFS were 0.85 (95% CI, 0.71 to 1.01; P = .07) in the intention-to-treat (n = 1,005), 0.83 (95% CI, 0.69 to 1.00) in the all-randomized stage II-IIIA (n = 882), and 0.70 (95% CI, 0.55 to 0.91) in stage II-IIIA PD-L1 tumor cell (TC) ≥1% (n = 476) populations. Stratified HRs (95% CI) for OS were 0.97 (95% CI, 0.78 to 1.22), 0.94 (95% CI, 0.75 to 1.19), and 0.77 (95% CI, 0.56 to 1.06), respectively. The unstratified HRs (95% CI) in the stage II-IIIA PD-L1 TC ≥50% population (n = 229) were 0.48 (95% CI, 0.32 to 0.72) for DFS and 0.47 (95% CI, 0.28 to 0.77) for OS, and the unstratified HRs in the stage II-IIIA PD-L1 TC ≥50% without EGFR / ALK alterations (n = 209) population were 0.49 (95% CI, 0.32 to 0.75) and 0.44 (95% CI, 0.26 to 0.74). No new safety signals were reported. IMpower010 is the first study to report survival outcomes with a ≥5-year follow-up and continued to show benefit with atezolizumab versus BSC after adjuvant chemotherapy in patients with resected stage II-IIIA PD-L1–selected NSCLC.


  • Open Access

    COMPARATIVE ANALYSIS OF BONE HEALING UNDER PHYSIOLOGICAL AND TRACE ELEMENT OVERLOAD CONDITIONS IN SENILE RATS

    by Hanna Lohvyniuk, Yevheniia Husak, Ihor Vynnychenko, Oleksandr Solodovnyk

    Introduction. Age-related impairment of bone healing is a growing clinical concern. While the role of trace elements in bone metabolism is well recognized, their effect on cancellous bone regeneration in elderly organisms remains poorly understood. Our study contributes a valuable foundation for understanding how excess exposure to specific trace elements – namely zinc (Zn), manganese (Mn), copper (Cu), lead (Pb), and chromium (Cr) – affects bone regeneration. Through a comparative histological and ultrastructural analysis of fracture healing in control and microelement-overload groups, we aim to elucidate the mechanisms by which trace elements modulate bone repair, angiogenesis, and osteogenesis in aged organisms. Methods. Our study was focused on comparing the course of cancellous bone healing under physiological conditions and trace element overconsumption in senile rats using histological and scanning electron microscopy analysis. Results. The results showed cancellous bone healing of control group followed a time-dependent sequence of inflammation, granulation tissue formation, fibroreticular remodeling, and coarse woven bone deposition. In contrast, the trace element overconsuption group exhibited delayed and disorganized reparative osteogenesis, marked by delay tissue formation, prolonged inflammatory features, and substantial cartilaginous tissue formation by day 21. Reduced vascular density in MeG animals suggested impaired angiogenesis, further contributing to compromised regeneration. Conclusions. Trace element overconsumption alters the normal trajectory of cancellous bone healing in senile rats, inducing a shift toward endochondral ossification and impairing vascularization. These findings underscore the critical influence of microelement balance on skeletal repair in aging organisms.

  • Open Access

    Supplementary Data 1 from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

    by Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, et al.

    Supplementary tables and figures

  • Open Access

    Supplementary Data 1 from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

    by Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, et al.

    Supplementary tables and figures

  • Open Access

    Data from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

    by Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, et al.

    Purpose:The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC).Patients and Methods:Patients with ES-SCLC with progressive disease during or within 90 days of completing first-line platinum-based chemotherapy received one of three regimens: durvalumab plus tremelimumab followed by durvalumab monotherapy (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C). The primary endpoint was the objective response rate. Prespecified exploratory biomarker analyses were conducted in arms A and C.Results:In arm A (n = 41), arm B (n = 10), and arm C (n = 21), the confirmed objective response rates were 7.3%, 0%, and 4.8%, respectively. Safety profiles in all arms were consistent with those of the individual drugs. In arm A, patients with PD-L1 expression (tumor cells or immune cells) ≥1% seemed to have a greater likelihood of achieving disease control with durvalumab plus tremelimumab than those with PD-L1 (tumor cells and immune cells) <1%, and lower baseline ctDNA and reduction in the on-treatment ctDNA level were both associated with longer overall survival. Among patients treated with ceralasertib plus olaparib in arm C, specific immune response-relevant circulating chemokines and cytokines were identified as early biomarkers of survival and pharmacodynamic biomarkers.Conclusions:In BALTIC, all combination regimens demonstrated tolerable safety profiles, but antitumor activity was limited in refractory/resistant ES-SCLC. Among patients treated with durvalumab plus tremelimumab, an association of on-treatment reduction in ctDNA with longer overall survival suggests the potential use of ctDNA as a surrogate of treatment response, warranting further investigation.

  • Open Access

    Data from Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

    by Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, et al.

    Purpose:The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC).Patients and Methods:Patients with ES-SCLC with progressive disease during or within 90 days of completing first-line platinum-based chemotherapy received one of three regimens: durvalumab plus tremelimumab followed by durvalumab monotherapy (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C). The primary endpoint was the objective response rate. Prespecified exploratory biomarker analyses were conducted in arms A and C.Results:In arm A (n = 41), arm B (n = 10), and arm C (n = 21), the confirmed objective response rates were 7.3%, 0%, and 4.8%, respectively. Safety profiles in all arms were consistent with those of the individual drugs. In arm A, patients with PD-L1 expression (tumor cells or immune cells) ≥1% seemed to have a greater likelihood of achieving disease control with durvalumab plus tremelimumab than those with PD-L1 (tumor cells and immune cells) <1%, and lower baseline ctDNA and reduction in the on-treatment ctDNA level were both associated with longer overall survival. Among patients treated with ceralasertib plus olaparib in arm C, specific immune response-relevant circulating chemokines and cytokines were identified as early biomarkers of survival and pharmacodynamic biomarkers.Conclusions:In BALTIC, all combination regimens demonstrated tolerable safety profiles, but antitumor activity was limited in refractory/resistant ES-SCLC. Among patients treated with durvalumab plus tremelimumab, an association of on-treatment reduction in ctDNA with longer overall survival suggests the potential use of ctDNA as a surrogate of treatment response, warranting further investigation.

  • Open Access

    Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

    by Niels Reinmuth, Oscar Juan-Vidal, Dariusz Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, et al.

    Purpose: The phase II, multiarm, signal-searching BALTIC study (NCT02937818) assessed novel treatment combinations for platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC). Patients and Methods: Patients with ES-SCLC with progressive disease during or within 90 days of completing first-line platinum-based chemotherapy received one of three regimens: durvalumab plus tremelimumab followed by durvalumab monotherapy (arm A), adavosertib plus carboplatin (arm B), or ceralasertib plus olaparib (arm C). The primary endpoint was the objective response rate. Prespecified exploratory biomarker analyses were conducted in arms A and C. Results: In arm A (n = 41), arm B (n = 10), and arm C (n = 21), the confirmed objective response rates were 7.3%, 0%, and 4.8%, respectively. Safety profiles in all arms were consistent with those of the individual drugs. In arm A, patients with PD-L1 expression (tumor cells or immune cells) ≥1% seemed to have a greater likelihood of achieving disease control with durvalumab plus tremelimumab than those with PD-L1 (tumor cells and immune cells) <1%, and lower baseline ctDNA and reduction in the on-treatment ctDNA level were both associated with longer overall survival. Among patients treated with ceralasertib plus olaparib in arm C, specific immune response-relevant circulating chemokines and cytokines were identified as early biomarkers of survival and pharmacodynamic biomarkers. Conclusions: In BALTIC, all combination regimens demonstrated tolerable safety profiles, but antitumor activity was limited in refractory/resistant ES-SCLC. Among patients treated with durvalumab plus tremelimumab, an association of on-treatment reduction in ctDNA with longer overall survival suggests the potential use of ctDNA as a surrogate of treatment response, warranting further investigation.


  • 80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

    by E. Felip, N.K. Altorki, C. Zhou, E. Vallieres, I.O. Vynnychenko, A. Akopov, A. Martinez-Marti, A. Chella, I. Bondarenko, G. Ursol, et al.


  • Open Access

    Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review)

    by O.M. Smorodska, Yu.V. Moskalenko, I.O. Vynnychenko, O.I. Vynnychenko, V.V. Kostuchenko

    Tumor molecular profiling in patients with non-small cell lung cancer (NSCLC) is used to identify driver mutations, which lead to premature carcinogenesis in more than 80% of adenocarcinoma cases, including epidermal growth factor receptor (EGFR) mutations. Identification of specific somatic aberrations allows to personalize treatment. Personalization of treatment resulted in improvement of NSCLC outcomes. The aim of our study was to consider scientific data on modern concepts of treatment of patients with non-small cell lung cancer with previously detected oncogenic mutations, especially EGFR mutation. In our study we analyzed scientific papers and data of international scientific literature on the problem of lung cancer treatment. Methods used: scientific research, analytical and generalizing. Different drugs are used in treatment of lung cancer. Choice of treatment scheme depends on type and presence of mutations. Patients with advanced non-small-cell lung cancer and detected mutation in the EGFR can be treated with tyrosine kinase inhibitors (TKIs). Nowadays three first generation drugs are recommended by FDA: afatinib, erlotinib, gefitinib. They showed good clinical benefit. Most patients with metastatic NSCLC typically show disease progression after approximately 9 to 13 months of erlotinib, gefitinib, or afatinib therapy. The first and only commercially available third-generation EGFR TKI is оsimertinib - an oral drug, which selectively inhibits both EGFR-TKI and EGFR T790M resistance mutations. Nowadays scientists are in active investigation of mechanisms of acquired resistance to TKIs, but little is known yet. Clinical success can be observed in patients who were treated with TKIs. EGFR T790M is a mutation that leads to acquired resistance to EGFR TKI therapy. Its incidence is approximately 60% after disease progression on TKI drugs (erlotinib, gefitinib, or aphatinib). Third-generation EGFR TKIs demonstrate high efficacy, but acquired resistance development cannot be avoided. Mechanisms of acquired resistance to these agents are still investigated.